Recent Analysts’ Ratings Changes for Vertex Pharmaceuticals (VRTX)

Several brokerages have updated their recommendations and price targets on shares of Vertex Pharmaceuticals (NASDAQ: VRTX) in the last few weeks:

  • 10/24/2019 – Vertex Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 10/22/2019 – Vertex Pharmaceuticals had its price target raised by analysts at Credit Suisse Group AG from $213.00 to $221.00. They now have an “overweight” rating on the stock.
  • 10/22/2019 – Vertex Pharmaceuticals had its price target raised by analysts at Leerink Swann from $186.00 to $203.00. They now have a “market perform” rating on the stock.
  • 10/22/2019 – Vertex Pharmaceuticals had its price target raised by analysts at Citigroup Inc from $205.00 to $225.00. They now have a “buy” rating on the stock.
  • 10/21/2019 – Vertex Pharmaceuticals was given a new $232.00 price target on by analysts at BMO Capital Markets. They now have a “buy” rating on the stock.
  • 10/21/2019 – Vertex Pharmaceuticals was given a new $220.00 price target on by analysts at Jefferies Financial Group Inc. They now have a “buy” rating on the stock.
  • 10/21/2019 – Vertex Pharmaceuticals was given a new $220.00 price target on by analysts at Cowen Inc. They now have a “buy” rating on the stock.
  • 10/21/2019 – Vertex Pharmaceuticals was given a new $210.00 price target on by analysts at Robert W. Baird. They now have a “buy” rating on the stock.
  • 10/21/2019 – Vertex Pharmaceuticals was given a new $218.00 price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 10/16/2019 – Vertex Pharmaceuticals is now covered by analysts at Bank of America Corp. They set a “buy” rating and a $220.00 price target on the stock.
  • 10/8/2019 – Vertex Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/1/2019 – Vertex Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 9/23/2019 – Vertex Pharmaceuticals had its price target raised by analysts at Jefferies Financial Group Inc from $210.00 to $220.00.
  • 9/10/2019 – Vertex Pharmaceuticals was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 9/6/2019 – Vertex Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $215.00 to $240.00. They now have an “overweight” rating on the stock.
  • 9/3/2019 – Vertex Pharmaceuticals was upgraded by analysts at Goldman Sachs Group Inc from a “neutral” rating to a “buy” rating. They now have a $254.00 price target on the stock, up previously from $226.00.
  • 8/28/2019 – Vertex Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.

NASDAQ:VRTX traded up $3.95 during trading hours on Thursday, hitting $194.46. The company had a trading volume of 124,355 shares, compared to its average volume of 1,215,556. The company has a market capitalization of $49.11 billion, a PE ratio of 68.71, a price-to-earnings-growth ratio of 2.31 and a beta of 1.43. The stock has a 50-day moving average price of $174.68 and a 200 day moving average price of $175.56. Vertex Pharmaceuticals Incorporated has a 52 week low of $151.80 and a 52 week high of $195.81. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.74 and a quick ratio of 3.63.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $0.99 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.24. The business had revenue of $941.29 million for the quarter, compared to analysts’ expectations of $884.66 million. Vertex Pharmaceuticals had a net margin of 64.13% and a return on equity of 21.73%. The firm’s revenue for the quarter was up 25.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.94 earnings per share. Analysts anticipate that Vertex Pharmaceuticals Incorporated will post 3.47 EPS for the current fiscal year.

In other news, Director Margaret G. Mcglynn sold 10,000 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $1,850,000.00. Following the sale, the director now owns 14,124 shares in the company, valued at approximately $2,612,940. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Stuart A. Arbuckle sold 2,155 shares of the business’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $177.78, for a total transaction of $383,115.90. Following the sale, the executive vice president now owns 34,395 shares in the company, valued at approximately $6,114,743.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 44,053 shares of company stock worth $7,912,908. 0.70% of the stock is currently owned by company insiders.

Several hedge funds have recently made changes to their positions in VRTX. Next Capital Management LLC boosted its holdings in shares of Vertex Pharmaceuticals by 84.4% during the 2nd quarter. Next Capital Management LLC now owns 166 shares of the pharmaceutical company’s stock valued at $30,000 after buying an additional 76 shares in the last quarter. Evolution Wealth Advisors LLC bought a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter valued at $32,000. Patriot Financial Group Insurance Agency LLC boosted its holdings in shares of Vertex Pharmaceuticals by 118.5% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 177 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 96 shares in the last quarter. HM Payson & Co. bought a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter valued at $35,000. Finally, Captrust Financial Advisors boosted its holdings in shares of Vertex Pharmaceuticals by 204.1% during the 2nd quarter. Captrust Financial Advisors now owns 222 shares of the pharmaceutical company’s stock valued at $41,000 after buying an additional 149 shares in the last quarter. Hedge funds and other institutional investors own 94.79% of the company’s stock.

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Featured Article: Growth Stocks, What They Are, What They Are Not

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.